Claims

20

25

What we claim is:

- 5 1. The use of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the treatment and / or prophylaxis of constipation, in a warm-blooded animal, such as man.
- A pharmaceutical composition which comprises an IBAT inhibitor, or a
 pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier for use in the treatment and / or prophylaxis of constipation.
- 3. The use of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment and / or prophylaxis of constipation, in a warm-blooded animal, such as man.
 - 4. A method of treatment and / or prophylaxis of constipation, in a warm-blooded animal, such as man, in need of such treatment and / or prophylaxis which comprises administering to said animal an effective amount of an IBAT inhibitor, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.
 - 5. The use or method according to claims 1-4 wherein the constipation is functional constipation.
 - 6. The use or method according to claims 1-4 wherein the constipation is constipation predominant irritable bowel syndrome.
- 7. The use or method of treatment according to any one of claims 1-6 wherein the IBAT 30 inhibitor is selected from:

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((R)-1-carboxy-2-methylthio$ ethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5benzothiadiazepine;
- hydroxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-5 benzothiadiazepine;
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((S)-1-carboxy-2-(S)-1]-\alpha-[N-((S)-1-carboxy-2-(S)-1]-\alpha-(S)-1]$ methylpropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5benzothiadiazepine;
- 10 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((S)-1-carboxybutyl)$ carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5benzothiadiazepine;
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((S)-1-carboxypropyl)\})$ carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 15 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((S)-1-carboxyethyl)$ carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; hydroxypropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5benzothiadiazepine;
- 20 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-(2-sulphoethyl)carbamoyl]-4$ hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((S)-1-(S)-1)])$ carboxyethyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5benzothiadiazepine;
- 25 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((R)-1-carboxy-2-(R)-\alpha-[N-((R)-1-carboxy-2-(R)-\alpha-(R)$ methylthioethyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5benzothiadiazepine;
 - carboxyethyl)carbamoyl]propyl}carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-
- 30 1,2,5-benzothiadiazepine; and

WO 2004/089350 PCT/GB2004/001396

- 32 -

- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)- α -[N-((S)-1-carboxy-2-methylpropyl)carbamoyl]benzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine;
- 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8- $(N-\{(R)-\alpha-[N-((S)-1-carboxypropyl)$
- 5 carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; and
 - 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-[N-((R)- α -carboxy-4-hydroxybenzyl)carbamoylmethoxy]-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine; or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

10